Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of Andrew Jackson as Chief Financial.
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group’s trust account be.
Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics.
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi.
Form 425 First Light Acquisition Filed by: First Light Acquisition Group, Inc streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.